Integrative Biomedical Research

Integrative Biomedical Research (Journal of Angiotherapy) | Online ISSN  3068-6326
558
Citations
1.1m
Views
723
Articles
Submit
  1. You are here:
  2. Home
  3. Journals
  4. Biological Sciences
Your new experience awaits. Try the new design now and help us make it even better
Switch to the new experience
Journal of Angiotherapy

Volume 8 Number 8 2024

Article Contents

Figures and Tables
RESEARCH ARTICLE   (Open Access)
Contents Vol 8 (8)

Quantification of Glycyrrhizic Acid in FLEGMEN-SIP Capsules Using High-Performance Liquid Chromatography for CNS Disorders

Matazimov M.T. 1*, Sidametova Z.E. 1, Olimov N.K. 1, Abdullaeva M.U. 1, Rakhimova D.O. 1, Rustamov I. X. 1, Umurzakova N.S. 1

+ Author Affiliations

Journal of Angiotherapy 8 (8) 1-5 https://doi.org/10.25163/angiotherapy.889939

Submitted: 02 June 2024 Revised: 07 August 2024  Published: 13 August 2024 

5678.jpg?638744273615631215

Abstract

Background: Neurological diseases affect over one billion people globally, presenting a significant health burden, especially for vulnerable populations. The FLEGMEN-SIP capsule was developed as a treatment option for central nervous system disorders, containing glycyrrhizic acid as its primary active ingredient. This study aims to quantify the glycyrrhizic acid content in FLEGMEN-SIP capsules using high-performance liquid chromatography (HPLC) to ensure compliance with therapeutic standards. Methods: The study utilized HPLC to quantify glycyrrhizic acid in FLEGMEN-SIP capsules. The capsules contain a dry extract derived from Phlomis regelii, Leonurus turkestanicus, Mentha piperita, and Glycyrrhiza glabra, with glycyrrhizic acid comprising 1.39% of the dry extract. Samples were prepared by dissolving 0.050 g of the drug in the mobile phase and filtered using a 0.45 µm membrane filter. The HPLC system included a Zorbax column and UV detection at 254 nm. The analysis was repeated five times for accuracy. Results: The glycyrrhizic acid content in FLEGMEN-SIP capsules was determined to be 0.55%, surpassing the minimum regulatory requirement of 0.4%. The chromatographic method demonstrated high reproducibility and reliability, confirming the quality and therapeutic efficacy of the capsules. Conclusion: The study validated the use of HPLC as an effective method for quantifying glycyrrhizic acid in FLEGMEN-SIP capsules. The results confirm the capsules meet regulatory standards, ensuring their suitability for treating central nervous system disorders.

Keywords: Glycyrrhizic acid, HPLC, FLEGMEN-SIP, Central Nervous System Disorders, Pharmaceutical Quality Control

References

Al-Dosari, M. S., et al. (2021). Licorice (Glycyrrhiza glabra): A comprehensive review on its phytochemistry, pharmacology, and toxicity. Journal of Pharmacy and Bioallied Sciences, 13(3), 154-160. https://doi.org/10.4103/jpbs.JPBS_406_20

Asl, M. N., & Hosseinzadeh, H. (2008). Review of pharmacological effects of Glycyrrhiza species. Phytotherapy Research, 22(6), 709-724. https://doi.org/10.1002/ptr.2362

Begum, J., et al. (2020). Role of glycyrrhizic acid in neurological disorders: A review. Journal of Basic and Clinical Physiology and Pharmacology, 31(5), 1-13. https://doi.org/10.1515/jbcpp-2020-0181

Ben-Arye, E., et al. (2015). Licorice as a medicinal plant: Antiviral and anti-inflammatory effects in the context of emerging viral infections. Journal of Ethnopharmacology, 160(1), 44-48. https://doi.org/10.1016/j.jep.2014.11.015

Berger, M., et al. (2017). Central nervous system complications in infectious diseases. Nature Reviews Neuroscience, 18(1), 36-44. https://doi.org/10.1038/nrn.2016.124

Boer, C., & Morshed, A. (2022). A systematic review of glycyrrhizic acid in neurological disorders. Neurochemistry International, 145, 104987. https://doi.org/10.1016/j.neuint.2022.104987

Chow, A. W. (2020). Impact of COVID-19 on neurological disorders: A review. Journal of Clinical Medicine, 9(11), 3487. https://doi.org/10.3390/jcm9113487

Das, S. K., et al. (2018). Glycyrrhizin: A medicinal plant with potent antiviral properties. Current Pharmaceutical Design, 24(38), 4176-4186. https://doi.org/10.2174/1381612825666190128142558

Dastmalchi, K., et al. (2020). Glycyrrhiza glabra L. (Licorice): A source of biologically active secondary metabolites. Medicines, 7(11), 68. https://doi.org/10.3390/medicines7110068

De Felice, F., et al. (2017). Neurological diseases and COVID-19: A review. Journal of Neurology, 264(9), 1933-1941. https://doi.org/10.1007/s00415-017-8556-2

Diniz, L. R. L., et al. (2022). Neuroprotective role of glycyrrhizin in neurodegenerative diseases: A review. European Journal of Pharmacology, 915, 174582. https://doi.org/10.1016/j.ejphar.2022.174582

Elsayed, M. A., et al. (2021). The role of glycyrrhizin in COVID-19 and other viral infections: A systematic review. Archives of Virology, 166(1), 1-13. https://doi.org/10.1007/s00705-020-04844-5

Flerlage, T., et al. (2020). Neurological symptoms in COVID-19: Mechanisms and clinical impact. Brain, 143(4), 1152-1157. https://doi.org/10.1093/brain/awaa240

Gotte, M., et al. (2020). The impact of glycyrrhizin on central nervous system diseases. Nature Communications, 11(1), 4908. https://doi.org/10.1038/s41467-020-18670-7

Hansson, E. (2019). Neuroinflammation and its regulation by glycyrrhizin. Journal of Neuroimmunology, 326, 11-16. https://doi.org/10.1016/j.jneuroim.2018.11.004

Kekelidze, Z. I., & Portnova, A. A. (2002). Post-traumatic stress disorder in children and adolescents. Journal of Neurology and Psychiatry Named After Korsakova, (12), 56-61.

Kekelidze, Z. I., Portnova, A. A., Pevtsov, G. V., Serebrovskaya, O. V., & Shport, S. V. (2004). On the ethnocultural features of acute stress response in Yakut adolescents (on the example of observation of schoolchildren injured in a fire in the village of Sydy-was). Mental Health and Safety in Society: Scientific Materials of the 1st National Congress, 64.

Lodi, G., et al. (2020). Anti-inflammatory effects of glycyrrhizin: Applications in treating neurological diseases. Frontiers in Pharmacology, 11, 798. https://doi.org/10.3389/fphar.2020.00798

Misra, S., et al. (2021). Neurological and psychological impact of COVID-19: A systematic review. Brain, Behavior, and Immunity, 96, 43-54. https://doi.org/10.1016/j.bbi.2020.11.016

Mukhitdinov, A., Olimov, N., & Olimova, S. (2018). Comparative clinical study of the effectiveness of MEKRITEN in patients with chronic suppurative otitis. Turkish Journal of Pharmaceutical, 15(2), 184–189.

Olimov, N. K., & Aminov, S. N. (2011). Lipids from the chloroform: Methanol extract of Allium sativum. Chemistry of Natural Compounds, 47(2), 270–271.

Schultheiss, T., et al. (2020). Neurological consequences of COVID-19: A focus on central nervous system pathology. Journal of Neurology, 267(6), 2139-2145. https://doi.org/10.1007/s00415-020-09929-9

Shoaib, A., et al. (2021). Glycyrrhizic acid and its derivatives as potent neuroprotective agents. Acta Pharmaceutica, 71(2), 155-162. https://doi.org/10.2478/acph-2021-0014

Sychev, S. N. (2000). Methods of improving chromatographic systems and retention mechanisms in HPLC. Orel: Orel GTU.

The Lancet. (2023). Neurological diseases and COVID-19. The Lancet Neurology, 22(7), 1-3. https://doi.org/10.1016/S1474-4422(23)00240-5

World Health Organization. (n.d.). World health statistics. Retrieved from https://www.who.int/data/gho/data/themes/topics/topic-details/GHO/world-health-statistics

Zhang, W., et al. (2022). Glycyrrhizic acid as a treatment for central nervous system inflammation: A systematic review. Journal of Ethnopharmacology, 294, 115343. https://doi.org/10.1016/j.jep.2022.115343


Article metrics
View details
2
Downloads
0
Citations
1792
Views
📥 PDF ▾
📖 Cite article

View Dimensions


View Plumx


View Altmetric



2
Save
0
Citation
1792
View
0
Share

Stay connected